Repare Therapeutics Stock Return On Equity

RPTX Stock

USD 3.32 0.17 5.40%

Repare Therapeutics fundamentals help investors to digest information that contributes to Repare Therapeutics' financial success or failures. It also enables traders to predict the movement of Repare Stock. The fundamental analysis module provides a way to measure Repare Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Repare Therapeutics stock.

		Last Reported	Projected for Next Year
	Return On Equity	(0.44)	(0.42)

Return On Equity is likely to rise to -0.42 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Repare Therapeutics Company Return On Equity Analysis

Repare Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Repare Therapeutics Return On Equity

-0.41

Most of Repare Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Repare Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Repare Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Repare Therapeutics is extremely important. It helps to project a fair market value of Repare Stock properly, considering its historical fundamentals such as Return On Equity. Since Repare Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Repare Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Repare Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Short Term Investments
Total Assets		0.98	0.95	-0.91	-0.82	0.47	0.61	0.86	0.49	0.98	1.0	0.96	0.99	0.96	0.9	0.65	0.83	0.6
Total Stockholder Equity	0.98		0.98	-0.88	-0.82	0.42	0.61	0.84	0.31	1.0	0.98	0.98	0.97	0.98	0.9	0.63	0.84	0.61
Net Tangible Assets	0.95	0.98		-0.83	-0.86	0.47	0.67	0.87	0.26	0.98	0.95	0.99	0.94	0.99	0.94	0.6	0.89	0.64
Net Debt	-0.91	-0.88	-0.83		0.56	-0.6	-0.37	-0.62	-0.51	-0.88	-0.91	-0.81	-0.94	-0.81	-0.7	-0.34	-0.57	-0.22
Retained Earnings	-0.82	-0.82	-0.86	0.56		-0.45	-0.89	-0.99	-0.27	-0.82	-0.81	-0.9	-0.78	-0.9	-0.87	-0.64	-0.96	-0.77
Accounts Payable	0.47	0.42	0.47	-0.6	-0.45		0.58	0.44	0.39	0.42	0.46	0.44	0.52	0.44	0.44	-0.29	0.31	-0.14
Net Receivables	0.61	0.61	0.67	-0.37	-0.89	0.58		0.82	0.16	0.61	0.61	0.69	0.6	0.69	0.76	0.33	0.75	0.59
Capital Surpluse	0.86	0.84	0.87	-0.62	-0.99	0.44	0.82		0.34	0.84	0.85	0.91	0.82	0.91	0.85	0.68	0.96	0.75
Total Liab	0.49	0.31	0.26	-0.51	-0.27	0.39	0.16	0.34		0.31	0.49	0.31	0.5	0.31	0.36	0.31	0.24	0.2
Net Invested Capital	0.98	1.0	0.98	-0.88	-0.82	0.42	0.61	0.84	0.31		0.98	0.98	0.97	0.98	0.9	0.63	0.84	0.61
Total Current Assets	1.0	0.98	0.95	-0.91	-0.81	0.46	0.61	0.85	0.49	0.98		0.96	0.99	0.96	0.9	0.65	0.83	0.61
Capital Stock	0.96	0.98	0.99	-0.81	-0.9	0.44	0.69	0.91	0.31	0.98	0.96		0.94	1.0	0.94	0.66	0.93	0.69
Net Working Capital	0.99	0.97	0.94	-0.94	-0.78	0.52	0.6	0.82	0.5	0.97	0.99	0.94		0.94	0.88	0.57	0.78	0.53
Common Stock	0.96	0.98	0.99	-0.81	-0.9	0.44	0.69	0.91	0.31	0.98	0.96	1.0	0.94		0.94	0.66	0.93	0.69
Property Plant Equipment	0.9	0.9	0.94	-0.7	-0.87	0.44	0.76	0.85	0.36	0.9	0.9	0.94	0.88	0.94		0.64	0.89	0.76
Current Deferred Revenue	0.65	0.63	0.6	-0.34	-0.64	-0.29	0.33	0.68	0.31	0.63	0.65	0.66	0.57	0.66	0.64		0.74	0.91
Short Term Debt	0.83	0.84	0.89	-0.57	-0.96	0.31	0.75	0.96	0.24	0.84	0.83	0.93	0.78	0.93	0.89	0.74		0.83
Short Term Investments	0.6	0.61	0.64	-0.22	-0.77	-0.14	0.59	0.75	0.2	0.61	0.61	0.69	0.53	0.69	0.76	0.91	0.83

Click cells to compare fundamentals

For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Competition

Predict Repare Therapeutics

Return On Equity Over Time

Repare Total Stockholder Equity

Total Stockholder Equity

183.03 Million

At this time, Repare Therapeutics' Total Stockholder Equity is fairly stable compared to the past year.

Based on the latest financial disclosure, Repare Therapeutics has a Return On Equity of -0.4117. This is 98.28% lower than that of the Biotechnology sector and 98.87% lower than that of the Health Care industry. The return on equity for all United States stocks is 32.81% higher than that of the company.

Repare Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Repare Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Repare Therapeutics could also be used in its relative valuation, which is a method of valuing Repare Therapeutics by comparing valuation metrics of similar companies.

Repare Therapeutics is currently under evaluation in return on equity category among its peers.

Repare Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Repare Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Repare Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Repare Fundamentals

	Return On Equity	-0.41
	Return On Asset	-0.23
	Profit Margin	(1.26) %
	Operating Margin	(1.39) %
	Current Valuation	(42.96 M)
	Shares Outstanding	42.51 M
	Shares Owned By Insiders	0.95 %
	Shares Owned By Institutions	83.62 %
	Number Of Shares Shorted	749.74 K
	Price To Book	0.77 X
	Price To Sales	2.01 X
	Revenue	51.13 M
	Gross Profit	15.11 M
	EBITDA	(114.27 M)
	Net Income	(93.8 M)
	Cash And Equivalents	282.09 M
	Cash Per Share	6.73 X
	Total Debt	3.41 M
	Debt To Equity	0.03 %
	Current Ratio	7.35 X
	Book Value Per Share	4.12 X
	Cash Flow From Operations	(127.16 M)
	Short Ratio	7.12 X
	Earnings Per Share	(1.99) X
	Target Price	12.5
	Number Of Employees	179
	Beta	0.71
	Market Capitalization	133.91 M
	Total Asset	253.9 M
	Retained Earnings	(333.11 M)
	Working Capital	204.61 M
	Net Asset	253.9 M

About Repare Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Repare Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Repare Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Repare Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC